Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...